Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
59.00-0.48 (-0.81%)
At close: 4:00PM EDT
59.00 0.00 (0.00%)
After hours: 05:23PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Insider Monkey

    Hedge Funds Are Crazy About Fate Therapeutics Inc (FATE)

    We at Insider Monkey have gone over 873 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th. In this article, we look at what those funds think of Fate Therapeutics Inc (NASDAQ:FATE) based on that […]

  • GlobeNewswire

    Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting

    SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The o

  • GlobeNewswire

    Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support

    Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK CellsSAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, announced today the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell p

Advertisement
Advertisement